Durham transit workers could go on strike next month, region warns
Transit riders in Durham Region could be looking at a service disruption next month following another step toward possible strike action by workers.
Bill Holmes, the general manager of Durham Region Transit (DRT), said in a statement Friday that Ontario's Ministry of Labour issued a No Board Report on May 21 following a request from the union.
The move means that frontline DRT workers, represented by Unifor Local 222, will be in a legal strike position as of June 7.
'Despite 12 days of negotiations, Durham Region Transit and Unifor Local 222 have been unable to reach a renewed collective agreement,' Holmes said in his statement.
He said that DRT is not able to provide any certainty or assurances at the moment but will provide more detailed information regarding any possible labour disruption as it becomes available.
'DRT and the Region remain committed to securing a deal with Unifor and our employees that is both fair and fiscally responsible,' he said.
The union said Thursday that DRT workers voted 98 per cent in favour of a strike mandate earlier this week if talks fail to produce an agreement.
They said the main sticking pint in the negotiations revolves around wages.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
4 minutes ago
- National Post
Harvest Announces TSX Listing of Canadian High Income Shares ETFs to Complement Harvest Diversified High Income Shares ETF Offering
Article content OAKVILLE, Ontario — Harvest Portfolios Group Inc. ('Harvest' 'Harvest ETFs') is pleased to announce the completion of the initial offering of ETF Shares of the Canadian Harvest High Income Shares ETFs and the Class A Units of the Harvest Canadian High Income Shares ETF (the 'ETFs'), outlined in the table below, pursuant to a prospectus dated August 19, 2025, filed with the securities regulatory authorities in all of the Canadian provinces and territories. The ETF Shares and the Class A Units will commence trading on the Toronto Stock Exchange ('TSX') today under the following ticker symbols outlined in the table below. Article content Article content As Canada's largest and leading single-stock ETF issuer, Harvest ETFs is expanding its product line-up with the new Canadian High Income Shares ETFs, which builds on the success of the High Income Shares TM suite. Designed to deliver high monthly income by investing in some of Canada's most recognizable companies, each ETF will hold a leading Canadian blue-chip company, offering exposure to sector growth potential while using modest leverage and an active covered call strategy to generate high monthly income for investors. Article content 'On the back of strong demand from Canadians who have looked for ways to invest in the Canadian story, we're incredibly excited to be able to empower investors to take advantage of local-led growth with high monthly income through this Canadian expansion of our High Income Shares TM suite of single-stock ETFs', said Michael Kovacs, President and CEO of Harvest ETFs, 'The 10 new ETFs include widely held market leaders that represent the growth engine of Canadian commerce, and through our underlying covered call option strategies, can deliver high levels of tax-efficient, monthly income for investors. In addition, similar to the category-leading Harvest Diversified High Income Shares ETF (TSX: HHIS) we are launching a new diversified High Income Shares TM one-ticket solution, the Harvest Canadian High Income Shares ETF (TSX: HHIC), initially focused on the 10 underlying Canadian Single Stock Securities.' Article content Distribution Announcement Article content The initial monthly variable distribution for the Canadian Harvest High Income Shares ETFs and the Harvest Canadian High Income Shares ETF will be paid on or about October 9, 2025 to securityholders of record on September 29, 2025 with an ex-dividend date of September 29, 2025. The ETFs names, tickers, and initial monthly variable distribution amount per share/unit are outlined in the table below. Article content ETFs TSX Ticker Initial Monthly Variable Distribution Harvest Agnico Eagle Enhanced High Income Shares ETF AEME $0.1600 per share Harvest BCE Enhanced High Income Shares ETF BCEE $0.1400 per share Harvest Cameco Enhanced High Income Shares ETF CCOE $0.2200 per share Harvest CNQ Enhanced High Income Shares ETF CNQE $0.1500 per share Harvest Enbridge Enhanced High Income Shares ETF ENBE $0.1300 per share Harvest Royal Bank Enhanced High Income Shares ETF RYHE $0.1100 per share Harvest Shopify Enhanced High Income Shares ETF SHPE $0.2500 per share Harvest Suncor Enhanced High Income Shares ETF SUHE $0.1400 per share Harvest TD Bank Enhanced High Income Shares ETF TDHE $0.1300 per share Harvest TELUS Enhanced High Income Shares ETF TEHE $0.1200 per share Harvest Canadian High Income Shares ETF HHIC $0.1600 per unit Article content Investment Objectives Article content The ETFs will seek to provide securityholders with (i) long-term capital appreciation by investing, directly or indirectly, on a levered basis, in the common shares of blue-chip well-known Canadian companies and (ii) high monthly cash distributions. Article content Investment Dealers can access and download certain regulatory documents relating to the Canadian Harvest High Income Shares ETFs and the Harvest Canadian High Income Shares ETF such as the ETF Facts and prospectus via the Harvest website at For additional information: Please visit e-mail info@ or call toll free 1-866-998-8298. Article content Article content Article content E-mail: Article content Article content LinkedIn: Article content Article content Twitter: Article content Article content Article content Facebook: Article content Article content Article content YouTube: Article content You will usually pay brokerage fees to your dealer if you purchase or sell shares/units of the investment fund on the TSX. If the shares/units are purchased or sold on the TSX, investors may pay more than the current net asset value when buying shares/units of the investment fund and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning shares/units of an investment fund. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. An investment fund must prepare disclosure documents that contain key information about the investment fund. You can find more detailed information about the investment fund in these documents. Distributions are paid to you in cash unless you request, pursuant to your participation in a distribution reinvestment plan, that they be reinvested into shares or units of the Fund. If the Fund earns less than the amounts distributed, the difference is a return of capital. Tax, investment and all other decisions should be made with guidance from a qualified professional. Article content Article content Article content Article content Article content Contacts Article content For Additional Information: Article content Website: Article content Article content Article content E-mail: Article content Article content Article content
Globe and Mail
4 minutes ago
- Globe and Mail
Tier One Silver Announces Termination of LIFE Offering
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - Tier One Silver Inc. (TSXV: TSLV) (OTCQB: TSLVF) ("Tier One" or the "Company") announces that the proposed private placement equity financing, being offered pursuant to a listed issuer financing exemption ("LIFE") offering document filed on June 23, 2025, will not be proceeding. The Company will be contacting participating subscribers and their brokers to arrange the return of any funds which were advanced. Tier One is seeking alternative financing options and will make an announcement in this regard if and when arranged. About Tier One Silver Tier One Silver is an exploration company focused on creating value for shareholders and stakeholders through the discovery of world-class silver, gold and copper deposits in Peru. The Company is focused on its flagship exploration project, Curibaya but continues to investigate other potential projects of merit. The Company's management and technical teams have a strong track record in raising capital, discovery and monetization of exploration success. ON BEHALF OF THE BOARD OF DIRECTORS OF TIER ONE SILVER INC. Peter Dembicki President, CEO and Director For further information on Tier One Silver Inc., please contact the Company at (778) 729-0700 or visit the Company's website: Capital Markets Contact: Julia Becker Forward-Looking Information and General Cautionary Language This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to the Company's current expectations and views of future events in connection with an alternative financing. Forward-looking statements are not historical facts and therefore may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be heavily relied upon. These statements speak only as of the date of this news release. In particular, and without limitation, this news release contains forward-looking statements in regard to arranging an alternative financing. Readers should refer to the risks discussed in the Company's Annual Information Form for the year ended December 31, 2023, and subsequent continuous disclosure filings with the Canadian Securities Administrators available at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Globe and Mail
14 minutes ago
- Globe and Mail
Quantum BioPharma Announces Corporate Updates
TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (' Quantum BioPharma ' or the ' Company '), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates: Debt Settlement On August 12, 2025, the board of directors of the Company (the ' Board ') authorized the settlement of outstanding debt with one (1) creditor in the amount of $26,812.50 USD by converting the debt into 1,102 Class B Shares (' Creditor Shares ') at a deemed price of $24.33 USD per Class B Share. Grant of Restricted Stock Units On August 15, 2025, the Board authorized and approved the grant of restricted share units (each, an ' RSU ') pursuant to the Equity Incentive Plan. The Company granted 800 RSUs each to Peter Stys and Jack Antel (each a ' Clinical Advisor '). The RSUs granted vest in accordance with the following schedule: 500 RSUs will vest to each Clinical Advisor when the Company has a filing application with the US FDA or an equivalent regulatory filing in another country for the start of a clinical Phase 2 trial for Lucid MS within 1 year of grant. 300 RSUs will vest to each Clinical Advisor when the Company receives a no objection letter or an equivalent regulatory approval from the US FDA or other regulatory institution permitting the start of the clinical trial. Statutory Hold Period and Restrictions on Resale The Creditor Shares and RSUs (and any Class B Shares issuable upon their settlement) are subject to a statutory hold period of four months and one day pursuant to the policies of the CSE. The RSU's and Creditor Shares were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein. Change to Advisory Board Effective August 15, 2025, the Company terminated the Board Advisor Agreement dated July 1, 2025, with Kevin Malone, and as a result, Mr. Malone is no longer serving as an Advisor to the Company's Board of Directors. About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (' Lucid '), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (' Celly Nutrition '), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit Forward-Looking Information This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma's filings on SEDAR+ ( and EDGAR ( Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law. The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Contacts:
